[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100557089":3},{"organization":4,"armGroups":7,"interventions":17,"overallOfficials":32,"centralContacts":36,"locations":46,"responsibleParty":214,"collaborators":11,"id":216,"slug":217,"hasResults":218,"nctId":219,"briefTitle":220,"officialTitle":221,"acronym":11,"eligibilityCriteria":222,"healthyVolunteers":218,"sex":223,"minAge":224,"maxAge":225,"enrollmentInfo":226,"targetDuration":11,"studyType":229,"phases":230,"briefSummary":233,"conditions":234,"keywords":248,"overallStatus":49,"whyStopped":11,"lastUpdateSubmitDate":252,"lastUpdatePostDateStruct":253,"startDateStruct":256,"completionDateStruct":258,"leadSponsor":260,"locationsCount":261},{"fullName":5,"class":6},"Vironexis Biotherapeutics Inc.","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Group 1\u002FGroup 2\u002FGroup 3\u002FGroup 4","EXPERIMENTAL",null,[13,14,15,16],"Genetic: Dose Level 1, VNX-101","Genetic: Dose Level 2, VNX-101","Genetic: Dose Level 3, VNX-101","Genetic: Dose Level 4, VNX-101",[18,23,26,29],{"type":19,"name":20,"description":21,"armGroupLabels":22,"otherNames":11},"GENETIC","Dose Level 1, VNX-101","Adeno-associated viral vector encoding the CD3\u002FCD19 Bi-Specific T-Cell Engager (AAV.CD3\u002FCD19), Single IV infusion",[9],{"type":19,"name":24,"description":21,"armGroupLabels":25,"otherNames":11},"Dose Level 2, VNX-101",[9],{"type":19,"name":27,"description":21,"armGroupLabels":28,"otherNames":11},"Dose Level 3, VNX-101",[9],{"type":19,"name":30,"description":21,"armGroupLabels":31,"otherNames":11},"Dose Level 4, VNX-101",[9],[33],{"name":34,"affiliation":5,"role":35},"Vironexis Clinical Trials","STUDY_DIRECTOR",[37,42],{"name":38,"role":39,"phone":40,"phoneExt":11,"email":41},"Allen Reha","CONTACT","908-938-6019","allen.reha@vironexis.com",{"name":43,"role":39,"phone":44,"phoneExt":11,"email":45},"Recruitment Partner: PatientWing","213-459-2979","studies@patientwing.com",[47,68,82,96,109,120,139,154,169,184,199],{"facility":48,"status":49,"city":50,"state":51,"zip":52,"country":53,"countryCode":54,"cosmosGeoPoint":55,"geoPoint":60,"contacts":61},"City of Hope","RECRUITING","Duarte","California","91010","United States","US",{"type":56,"coordinates":57},"Point",[58,59],-117.97729,34.13945,{"lat":59,"lon":58},[62,66],{"name":63,"role":39,"phone":64,"phoneExt":11,"email":65},"Anthony Stein, MD","877-467-3411","AStein@coh.org",{"name":63,"role":67,"phone":11,"phoneExt":11,"email":11},"PRINCIPAL_INVESTIGATOR",{"facility":69,"status":49,"city":70,"state":51,"zip":71,"country":53,"countryCode":54,"cosmosGeoPoint":72,"geoPoint":76,"contacts":77},"Valkyrie Clinical Trials","Los Angeles","90067",{"type":56,"coordinates":73},[74,75],-118.24368,34.05223,{"lat":75,"lon":74},[78],{"name":79,"role":39,"phone":80,"phoneExt":11,"email":81},"Myo Zaw","424-535-1874","clinicaltrials@vctcare.com",{"facility":83,"status":49,"city":84,"state":85,"zip":86,"country":53,"countryCode":54,"cosmosGeoPoint":87,"geoPoint":91,"contacts":92},"Colorado Blood Cancer Institute","Denver","Colorado","80218",{"type":56,"coordinates":88},[89,90],-104.9847,39.73915,{"lat":90,"lon":89},[93],{"name":94,"role":39,"phone":95,"phoneExt":11,"email":11},"Clinical Trial Information Line","720-754-4835",{"facility":97,"status":49,"city":98,"state":99,"zip":100,"country":53,"countryCode":54,"cosmosGeoPoint":101,"geoPoint":105,"contacts":106},"Mayo Clinic, Clinical Trials Referral Office","Jacksonville","Florida","32224",{"type":56,"coordinates":102},[103,104],-81.65565,30.33218,{"lat":104,"lon":103},[107],{"name":11,"role":39,"phone":108,"phoneExt":11,"email":11},"855-776-0015",{"facility":97,"status":49,"city":110,"state":111,"zip":112,"country":53,"countryCode":54,"cosmosGeoPoint":113,"geoPoint":117,"contacts":118},"Rochester","Minnesota","55905",{"type":56,"coordinates":114},[115,116],-92.4699,44.02163,{"lat":116,"lon":115},[119],{"name":11,"role":39,"phone":108,"phoneExt":11,"email":11},{"facility":121,"status":49,"city":122,"state":123,"zip":124,"country":53,"countryCode":54,"cosmosGeoPoint":125,"geoPoint":129,"contacts":130},"New York Medical College","Valhalla","New York","10595",{"type":56,"coordinates":126},[127,128],-73.77513,41.07482,{"lat":128,"lon":127},[131,135,138],{"name":132,"role":39,"phone":133,"phoneExt":11,"email":134},"Mitchell Cairo, MD","(914) 594-2150","mitchell_cairo@nymc.edu",{"name":136,"role":39,"phone":11,"phoneExt":11,"email":137},"Lauren Harrison","lauren_harrison@nymc.edu",{"name":132,"role":67,"phone":11,"phoneExt":11,"email":11},{"facility":140,"status":49,"city":141,"state":142,"zip":143,"country":53,"countryCode":54,"cosmosGeoPoint":144,"geoPoint":148,"contacts":149},"University of North Carolina at Chapel Hill\u002F University of North Carolina Medical Center","Chapel Hill","North Carolina","27599",{"type":56,"coordinates":145},[146,147],-79.05584,35.9132,{"lat":147,"lon":146},[150],{"name":151,"role":39,"phone":152,"phoneExt":11,"email":153},"Lacey Williams, MD","919-445-9676","Lacey_Williams@med.unc.edu",{"facility":155,"status":49,"city":156,"state":157,"zip":158,"country":53,"countryCode":54,"cosmosGeoPoint":159,"geoPoint":163,"contacts":164},"The Ohio State University Wexner Medical Center","Columbus","Ohio","43210",{"type":56,"coordinates":160},[161,162],-82.99879,39.96118,{"lat":162,"lon":161},[165],{"name":166,"role":39,"phone":167,"phoneExt":11,"email":168},"Gregory Behbehani, MD, PhD","614-293-3316","gregory.behbehani@osumc.edu",{"facility":170,"status":49,"city":171,"state":172,"zip":173,"country":53,"countryCode":54,"cosmosGeoPoint":174,"geoPoint":178,"contacts":179},"Oregon Health & Science University","Portland","Oregon","97239",{"type":56,"coordinates":175},[176,177],-122.67621,45.52345,{"lat":177,"lon":176},[180],{"name":181,"role":39,"phone":182,"phoneExt":11,"email":183},"Knight Cancer Institute Clinical Trials","503-949-1080","trials@ohsu.edu",{"facility":185,"status":49,"city":186,"state":187,"zip":188,"country":53,"countryCode":54,"cosmosGeoPoint":189,"geoPoint":193,"contacts":194},"TriStar BMT","Nashville","Tennessee","37203",{"type":56,"coordinates":190},[191,192],-86.78444,36.16589,{"lat":192,"lon":191},[195],{"name":196,"role":39,"phone":197,"phoneExt":11,"email":198},"Stephen Strickland, MD","615-329-7274","stephen.strickland@hcahealthcare.com",{"facility":200,"status":49,"city":201,"state":202,"zip":203,"country":53,"countryCode":54,"cosmosGeoPoint":204,"geoPoint":208,"contacts":209},"University of Texas MD Anderson Cancer Center","Houston","Texas","77030",{"type":56,"coordinates":205},[206,207],-95.36327,29.76328,{"lat":207,"lon":206},[210],{"name":211,"role":39,"phone":212,"phoneExt":11,"email":213},"Nicholas J Short, MD","713-563-4485","NShort@Mdanderson.org",{"type":215,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100557089","phase-1-gene-therapy-for-cd19-positive-hematologic-malignancies-sentry-cd19-100557089",false,"NCT06533579","Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)","A Phase 1\u002F2 Safety, Dose-finding, and Pharmacokinetics Study of VNX-101 Gene Therapy in Patients With Relapsed or Refractory CD19-Positive Hematologic Malignancies (SENTRY-CD19)","Inclusion Criteria:\n\n* Age: Part 1: 18-90 years of age, Part 2: 13-90 years of age\n* Relapsed or refractory CD-19 positive leukemia or lymphoma as defined in the protocol\n* CD19-positive expression\n* AAV specified capsid total antibody \\\u003C1:400\n* Protocol-specified ranges for renal, liver, cardiac and pulmonary function\n* Protocol-specified ranges for hematology parameters\n\nExclusion Criteria:\n\n* Hepatoxicity (AST or ALT \\> 2x upper limit of normal)\n* History of thrombotic microangiopathy or cardiomyopathy, or evidence of sensory neuropathy\n* Pregnant or nursing (lactating) women\n* Acute Graft versus Host Disease (GvHD): Grade 2-4 or chronic GvHD of any grade\n* History of hypersensitivity to corticosteroids or history of corticosteroid-related toxicity\n* Chemotherapy given within the protocol-specified discontinuation timelines\n\nOther Inclusion\u002FExclusion criteria to be applied per protocol.","ALL","13 Years","90 Years",{"count":227,"type":228},32,"ESTIMATED","INTERVENTIONAL",[231,232],"PHASE1","PHASE2","This is a Phase 1\u002F2, first-in-human, open-label, dose-escalating trial designed to assess the safety and efficacy of VNX-101 in patients with relapsed or refractory CD19-positive hematologic malignancies.",[235,236,237,238,239,240,241,242,243,244,245,246,247],"B-cell Acute Lymphoblastic Leukemia","Large B-cell Lymphoma","Chronic Lymphocytic Leukemia","Small Lymphocytic Lymphoma","Marginal Zone Lymphoma","Follicular Lymphoma","Mantle Cell Lymphoma","Diffuse Large B Cell Lymphoma","High-grade B-cell Lymphoma","Burkitt Lymphoma","Primary Mediastinal Large B-cell Lymphoma (PMBCL)","Non Hodgkin Lymphoma","Mixed Phenotype Acute Leukemia",[249,250,251],"CD19-positive","Leukemia","Lymphoma","2026-08-04",{"date":254,"type":255},"2026-08-06","ACTUAL",{"date":257,"type":255},"2025-05-30",{"date":259,"type":228},"2031-09",{"name":5,"class":6},11]